HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MAM-06.301 Sensitive: D – Preclinical Cancer Cell Int - 1 week (New D) MAM-06.301 Sensitive : D Cancer Cell Int - 1wk	MAM-06.301 Sensitive: D – Preclinical Cancer Cell Int - 1 week MAM-06.301 Sensitive : D Cancer Cell Int - 1 week - (New D)
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks (New B) XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2wk	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2 weeks - (New B)
CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks (New D) CDK6 inhibitor Resistant : D Nat Commun - 2wk	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks CDK6 inhibitor Resistant : D Nat Commun - 2 weeks - (New D)
CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks (New D) CDK4 inhibitor Resistant : D Nat Commun - 2wk	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks CDK4 inhibitor Resistant : D Nat Commun - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) trastuzumab + pyrotinib Sensitive : B ESMO 2022 - 3wk	trastuzumab + pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks trastuzumab + pyrotinib Sensitive : B ESMO 2022 - 3 weeks - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) dalpiciclib Sensitive : B ESMO 2022 - 3wk	dalpiciclib Sensitive: B - Late Trials ESMO 2022 - 3 weeks dalpiciclib Sensitive : B ESMO 2022 - 3 weeks - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) RAD1901 Sensitive : B ESMO 2022 - 3wk	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks RAD1901 Sensitive : B ESMO 2022 - 3 weeks - (New B)
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ado-trastuzumab emtansine Sensitive : C3 ESMO 2022 - 3wk	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ado-trastuzumab emtansine Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation + HR positive	HER2 Negative Breast Cancer	BRCA2 mutation + HR positive	HER2 Negative Breast Cancer	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) niraparib Sensitive : C3 ESMO 2022 - 3wk	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks niraparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation + HR positive	HER2 Negative Breast Cancer	BRCA1 mutation + HR positive	HER2 Negative Breast Cancer	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) niraparib Sensitive : C3 ESMO 2022 - 3wk	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks niraparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + abemaciclib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + abemaciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + abemaciclib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	TAS-117 Sensitive: C4 – Case Studies ESMO 2022 - 3 weeks (New C4) TAS-117 Sensitive : C4 ESMO 2022 - 3wk	TAS-117 Sensitive: C4 – Case Studies ESMO 2022 - 3 weeks TAS-117 Sensitive : C4 ESMO 2022 - 3 weeks - (New C4)
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks (New A1) olaparib Sensitive : A1 AstraZeneca Press Release - 4wk	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks olaparib Sensitive : A1 AstraZeneca Press Release - 4 weeks - (New A1)
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks (New A1) olaparib Sensitive : A1 AstraZeneca Press Release - 4wk	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks olaparib Sensitive : A1 AstraZeneca Press Release - 4 weeks - (New A1)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	TAC Sensitive: A1 - Approval TAC Sensitive : A1	TAC Sensitive: A1 - Approval TAC Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1

Breast Cancer

Associations(1895)

Associations
(1895)